SEOUL, Jan. 31 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback